Absci Stock Plunges 14.81% on Public Offering

On July 25, 2025, Absci's stock experienced a significant drop of 14.81% in pre-market trading.

Absci has recently announced the pricing of a public offering of 16,670,000 shares of common stock at $3.00 per share. This move has led to a nearly 14% decline in the company's stock price in pre-market trading. The proceeds from this offering are intended to support the advancement of Absci's internal drug programs and continued development efforts.

The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $50 million. This public offering includes an additional option for $7.5 million in stock, managed by top financial institutions.